SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : IVAX, Generic Giant

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10PreviousNext  
To: Mark A. Stang who wrote (207)4/1/1998 10:05:00 PM
From: harkenman   of 212
 
Ivax Corp., Abbott Labs Settle Hytrin-Related Litigation

Dow Jones Newswires

MIAMI -- Ivax Corp. (IVX) settled its litigation against
Abbott Laboratories (ABT) regarding the marketing of
terazosin hydrochloride, the generic version of Abbott's
Hytrin product.

In a press release Wednesday, Ivax said it agreed to
dismiss its unfair competition and other business tort and
declaratory judgement claims against Abbott.

Abbott agreed to pay Ivax $6 million per calendar quarter
until the earlier of the expiration of an Abbott patent
scheduled to expire on Feb. 17, 2000, or the market
introduction of a generic version of terazosin hydrochloride
by any person other than Ivax.

The payments are scheduled to begin July 15, and Ivax
received one-half of the initial quarterly payment upon
signing of the settlement agreement.

Upon expiration of the patent or market introduction of a
generic version of terazosin hydrochloride, Ivax may market
terazosin hydrochloride free from claims of patent
infringement by Abbott, Ivax said.

Ivax's Zenith Goldline Pharmaceuticals unit currently has
an Abbreviated New Drug Application for terazosin
hydrochloride pending before the Food and Drug
Administration.

Ivax is a holding company with core units that research,
develop, manufacture and market generic and branded
pharmaceuticals.

interactive4.wsj.com
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10PreviousNext